Print Page   |   Contact Us   |   Sign In   |   Join
Latest News
Blog Home All Blogs
Find the latest news posted by ASAPA. SUBSCRIBE TO BE NOTIFIED OF POSTINGS: If you are logged in just click on the Subscribe link at the top of this page. If you are not logged in, you will need to log in and then navigate back to the blog and then click on the Subscribe link at the top of the page. COMMENT ON A POST You must be logged in to post comments. The comments box is located at the bottom of the post but can only be seen if you are logged in.

 

Search all posts for:   

 

Top tags: ADHS  Legislative  candidates  Election  Newsletter  Awards  blog  BOD  botanicals  CME  complimentary  Conference  herbal  HOD  Membership Dues  Opioid  PA History Society  subscribe  supplements  Veterans Caucus  yerberia 

PA Prescribing of Schedule II and III Controlled Substanced

Posted By Jen Feirstein, ASAPA Legislative Committee Chair, Tuesday, January 22, 2019
Updated: Tuesday, January 22, 2019

On January 17, 2019, ASAPA was made aware of many practicing PAs in Arizona being told by pharmacies that PAs can only prescribe a 72-hour supply of schedule II and III controlled substances.  The Association has been actively pursuing additional information and working to resolve the problem.

 

Here is what we know as of this writing:

 

During the 2018 legislative session, HB 2250 passed, which was intended to certify PAs for 90-day prescription privileges for non-opioid schedule II and III controlled substances.  Unfortunately, the final language that was passed in HB 2250 (attached) is being interpreted to restrict the prescribing of schedule II and III controlled substances to 72-hours.


HB 2250 was intended ONLY to increase the prescribing limits of non-opioid schedule II and III controlled substances to 90 days, and to otherwise leave prescribing privileges unchanged.  Unfortunately, explicit language was not included that indicated the ability to prescribe for up to 30 days was remaining unchanged. 


After HB 2250 passed, ASAPA testified at both the rule-making hearing and at the Arizona Regulatory Board of Physician Assistants (ARBOPA) board meeting expressing concerns about possible misinterpretation. 


ARBOPA now understands our concerns and we are working very closely with ARBOPA and our association lobbyist to identify the most expeditious solution to this problem.  Currently, it appears this will likely occur in the form of amending a fast-track bill moving through the Legislature to address e-prescribing issues associated with the enactment of the Opioid Act during the 2018 legislative session.  There is consensus among physicians and hospitals over the need to correct the interpretation that has created the prescribing limitation.


ASAPA will communicate updates with you as they are received.  Please be ready to reach out to your legislators, if needed.  We are aware of the significant burden this is placing on PAs, especially PAs practicing in pain management and other disciplines that regularly prescribe these medications.  Please know that we are doing everything in our power to resolve this barrier to PA practice and to the health care needs of our patients.


Sincerely,

Jennifer Feirstein, MSPAS, PA-C, DFAAPA
Chair, Legislative Committee
President
Arizona State Association of Physician Assistants

Tags:  Legislative 

Share |
PermalinkComments (1)
 

Voting Guide to the Arizona Ballot Propositions

Posted By Administration, Wednesday, October 3, 2018
Preparing for elections in November?  A Voting Guide to the Arizona Ballot Propositions has been prepared by the ASAPA lobbyist team at Goodman Schwartz Public Affairs.  ASAPA members can access this guide under the Members Only tab.  You must be logged in.

Tags:  Legislative 

Share |
PermalinkComments (0)
 

Impending Opioid E-Prescribing Mandate Guidance

Posted By Administration, Tuesday, September 11, 2018

Action Alert – Impending Opioid E-Prescribing Mandate Guidance

One of the most significant provisions of the Arizona Opioid Epidemic Act, SB 1001, is the prescriber electronic transmission requirements for prescribing opioids. Electronic prescribing of controlled substances (EPCS) mitigates prescription fraud to prevent the occurrence of fake prescriptions, as well as reduces prescribing errors and improves the accuracy of medication dispensing. These new requirements go into effect in 2019.

Opioid E-Prescribing Requirements
Beginning January 1, 2019, each prescription order for a Schedule II opioid in
Maricopa, Mohave, Pima, Pinal, Yavapai, and Yuma counties must be transmitted electronically to the dispensing pharmacy. The only exception is for Medication Assisted Treatment (MAT) for substance use disorder, or if a waiver is granted to a prescriber (see below).

Beginning July 1, 2019, these same requirements go into effect in Greenlee, La Paz, Graham, Santa Cruz, Gila, Apache, Navajo, Cochise and Coconino counties.

Link to E-Prescribing Requirements in SB 1001 Bill Language

Take Action for Compliance
We urge you to assess your clinical practice capacities and determine if you are compliant with these impending opioid e-prescribing requirements to avoid and/or
minimize any disruption to your practice and patients.

It is important to note that e-prescribing controlled substances must satisfy the Drug Enforcement Administration’s Electronic Prescriptions for Controlled Substances (EPCS) system requirements and may cost more than basic e-prescribing. Many of the most common electronic health record vendors have both e-prescribing and EPCS capabilities so contact them for more information. To find out if your EHR vendor is EPCS-certified, you can also check the Surescripts website.

Request a Waiver, if Necessary
Pursuant to
Arizona Revised Statutes 36-2525 Q., the Arizona State Board of Pharmacy is required to grant waivers to medical practitioners who lack adequate access to broadband or face other hardships that prevent implementation of EPCS. The maximum duration for a waiver is up to one year.

If you determine you will be unable to meet the EPCS e-prescribing requirements, please submit a waiver using this link to the Arizona Board of Pharmacy as soon as possible: Waiver Form Link

DO NOT DELAY! The deadline to get a waiver to the Arizona Board of Pharmacy for consideration before 2019 is November 15, 2018. Once the waiver form is completely filled out, email the form to pmp@azpharmacy.gov.

Questions & Feedback?
If you have questions about EPCS, additional information is available on the Health Current website or you may contact them for phone-based support at 602-688-7200.

Tags:  Legislative  Opioid 

Share |
PermalinkComments (0)
 

ASAPA Sends Letter to U.S. Congress Regarding Medicaid

Posted By Administration, Friday, January 6, 2017
Download the attached document to view the letter.

Download File (PDF)

Tags:  Legislative 

Share |
PermalinkComments (2)
 
Membership Software Powered by YourMembership  ::  Legal